RecruitingPhase 4NCT06818474
Lanadelumab in Long-term Prophylaxis of Acquired Angioedema
Sponsor
Bernstein Clinical Research Center
Enrollment
5 participants
Start Date
Jun 1, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
use of lanadelumab in patients with acquired angioedema
Eligibility
Min Age: 18 Years
Inclusion Criteria2
- A diagnosis of AAE with recurrent attacks without urticaria (decreased C1INH functional, quantitative levels, decreased C4 and decreased C1q levels, no family history of angioedema), presence of anti-C1INH antibody and/or paraproteinemia (e.g. monoclonal gammopathy of unknown significance)
- historical attack rate of >= on attack per month prior to starting tranexamic acid (TAA)
Exclusion Criteria5
- History of anaphylaxis or hypersensitivity to biologics
- History of major systemic disease not well controlled in opinion of the PI
- Women who are pregnant or breast feeding
- Concurrent participation in other clinical trials
- HAE Type 1 or 2 and normal complement HAE
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
BIOLOGICALLanadelumab 300 mg
no other intervention
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06818474